>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat.No. SAD-S35) was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.472 μg/mL (QC tested).
Immobilized SARS-CoV-2 S1 protein, His Tag at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat.No. SAD-S35) was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 μg/mL (Routinely tested).
Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35) was incubated with SARS-CoV-2 pseudotyped virus at 37 °C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37 °C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat.No. SAD-S35) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD:ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1 mutant and treated with the antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD (A475V), His Tag (Cat. No. SPD-C52Hd) with an affinity constant of 87.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag (Cat. No. SPD-C5259) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S protein RBD used is 5μg/ml. The IC50 is 10.33 μg/ml (Routinely tested).
FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Cat. No. S1N-C5257) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S1 protein used is 3ug/ml. The IC50 is 1.352 μg/ml (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $380.00
Price(USD) : $2750.00
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methods, ACROBiosystems has developed a series of enzymes, such as IdeS, SpeB, EndoH, and Endo S proteases, to assist with the characterization of antibodies and their related post-translational modifications (PTMs).
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
This web search service is supported by Google Inc.